Targeting Secondary and Tertiary Resistance to BRAF Inhibition in BRAF V600E–Mutated Metastatic Colorectal Cancer-Reference-Cited by-同舟云学术

Targeting Secondary and Tertiary Resistance to BRAF Inhibition in BRAF V600E–Mutated Metastatic Colorectal Cancer

Published:2021-06 Issue:5 Volume: Page:1082-1087
ISSN:2473-4284
Container-title:JCO Precision Oncology
language:en
Short-container-title:JCO Precision Oncology

Author:

Akhoundova Dilara¹^ORCID,Pietge Heike¹^ORCID,Hussung Saskia¹,Kiessling Michael¹,Britschgi Christian¹,Zoche Martin²^ORCID,Rechsteiner Markus²,Weber Achim²,Fritsch Ralph M.¹^ORCID

Affiliation:

1. Department of Medical Oncology and Hematology, University Hospital of Zurich, Zurich, Switzerland

2. Department of Pathology and Molecular Pathology, University Hospital of Zurich, Zurich, Switzerland

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/PO.21.00107

Reference24 articles.

1. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer

2. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

3. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer

4. Capmatinib (INC280) Is Active Against Models of Non–Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation

5. BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of patients with BRAF-mutated metastatic colorectal cancer after progression to encorafenib and cetuximab: data from a real-world nationwide dataset;ESMO Open;2024-04

2. Targeting KRAS G12C Mutation in Colorectal Cancer, A Review: New Arrows in the Quiver;International Journal of Molecular Sciences;2024-03-14

3. Ezrin Inhibition Overcomes Acquired Resistance to Vemurafenib in BRAFV600E-Mutated Colon Cancer and Melanoma Cells In Vitro;International Journal of Molecular Sciences;2023-08-17

4. Tumor-Free Resection Margin Distance in the Surgical Treatment of Node-Negative Squamous Cell Cancer of the Vulva Has No Impact on Survival: Analysis of a Large Patient Cohort in a Tertiary Care Center;Cancers;2023-08-15

5. Unravelling the Complexity of Colorectal Cancer: Heterogeneity, Clonal Evolution, and Clinical Implications;Cancers;2023-08-08